Literature DB >> 8402063

Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis.

J A Windsor1, K C Fearon, J A Ross, G R Barclay, E Smyth, I Poxton, O J Garden, D C Carter.   

Abstract

It has been proposed that endotoxin contributes to the development of multiple organ failure (MOF) in acute pancreatitis. Endotoxaemia is transient and may not be detected by intermittent blood sampling. By contrast, not only can changes in the patient's endogenous antiendotoxin core antibody pool persist for many days, but depletion of this pool may be a key event in determining the physiological significance of endotoxaemia. A series of 33 patients with acute pancreatitis had daily measurement of Acute Physiology Score (APS) and levels of C-reactive protein, interleukin 6, endotoxin, immunoglobulin (Ig) G and IgM antiendotoxin core antibodies, and prospective documentation of complications. Endotoxin was detected in the serum of 13 patients, while a significant change in levels of endogenous antiendotoxin core antibodies was detected in all those with severe pancreatitis and in 28 overall. MOF developed in seven patients, five of whom died. The combination of a rising APS over the first 48 h of admission and a significant fall in endogenous IgG antibody level was observed in all patients who developed MOF (seven of seven), but in only one of 16 without MOF (P = 0.00003; overall predictive value 91 per cent). This study suggests that measuring the initial trend in APS and the concentration of endogenous IgG antiendotoxin core antibody provides a means of identifying patients with acute severe pancreatitis who are at high risk of developing MOF. This group might benefit from passive immunotherapy with antiendotoxin antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402063     DOI: 10.1002/bjs.1800800840

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  24 in total

1.  Role of cytokines and their inhibitors in acute pancreatitis.

Authors:  A Kingsnorth
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

2.  Detection and identification of bacterial DNA in serum from patients with acute pancreatitis.

Authors:  E de Madaria; J Martínez; B Lozano; L Sempere; S Benlloch; J Such; F Uceda; R Francés; M Pérez-Mateo
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

3.  Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis.

Authors:  R Berling; K Ohlsson
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

Review 4.  Severe acute pancreatitis: Clinical course and management.

Authors:  Hans G Beger; Bettina M Rau
Journal:  World J Gastroenterol       Date:  2007-10-14       Impact factor: 5.742

5.  Increased nitric oxide activity in a rat model of acute pancreatitis.

Authors:  R A Al-Mufti; R C Williamson; R T Mathie
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

6.  Lexipafant fails to improve survival in severe necrotizing pancreatitis in rats.

Authors:  J A Rivera; J Werner; A L Warshaw; K B Lewandrowski; D W Rattner; C Fernández del Castillo
Journal:  Int J Pancreatol       Date:  1998-04

7.  Is obesity a significant prognostic factor in acute pancreatitis?

Authors:  C J Tsai
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

8.  Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus.

Authors:  Audrey L French; Charlesnika T Evans; Denis M Agniel; Mardge H Cohen; Marion Peters; Alan L Landay; Seema N Desai
Journal:  J Infect Dis       Date:  2013-05-17       Impact factor: 5.226

9.  Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis.

Authors:  Sakhawat H Rahman; Basil J Ammori; John Holmfield; Michael Larvin; Michael J McMahon
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

10.  Monocyte TREM-1 membrane expression in non-infectious inflammation.

Authors:  Jean-Marc Cavaillon
Journal:  Crit Care       Date:  2009-06-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.